2.36
price up icon3.96%   0.09
after-market Dopo l'orario di chiusura: 2.34 -0.02 -0.85%
loading
Precedente Chiudi:
$2.27
Aprire:
$2.28
Volume 24 ore:
2.57M
Relative Volume:
0.57
Capitalizzazione di mercato:
$425.37M
Reddito:
$101.21M
Utile/perdita netta:
$-569.00K
Rapporto P/E:
-118.00
EPS:
-0.02
Flusso di cassa netto:
$-56.88M
1 W Prestazione:
+10.28%
1M Prestazione:
-10.94%
6M Prestazione:
+129.13%
1 anno Prestazione:
+77.44%
Intervallo 1D:
Value
$2.15
$2.38
Intervallo di 1 settimana:
Value
$2.10
$2.44
Portata 52W:
Value
$0.40
$3.095

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
Nome
Cytomx Therapeutics Inc
Name
Telefono
650.515.3185
Name
Indirizzo
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
Dipendente
121
Name
Cinguettio
@cytomxinc
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
CTMX's Discussions on Twitter

Confronta CTMX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CTMX
Cytomx Therapeutics Inc
2.36 425.37M 101.21M -569.00K -56.88M -0.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-15 Aggiornamento H.C. Wainwright Neutral → Buy
2025-04-14 Ripresa Piper Sandler Overweight
2024-05-28 Aggiornamento Piper Sandler Neutral → Overweight
2024-05-09 Aggiornamento Wedbush Neutral → Outperform
2024-05-06 Aggiornamento Jefferies Hold → Buy
2024-04-22 Aggiornamento JP Morgan Underweight → Neutral
2022-11-14 Downgrade BMO Capital Markets Outperform → Market Perform
2022-07-07 Downgrade Jefferies Buy → Hold
2022-07-07 Downgrade Mizuho Buy → Neutral
2022-07-07 Downgrade Piper Sandler Overweight → Neutral
2022-07-07 Downgrade Wedbush Outperform → Neutral
2022-06-24 Iniziato BMO Capital Markets Outperform
2022-01-18 Aggiornamento Barclays Underweight → Overweight
2021-11-15 Iniziato BTIG Research Buy
2021-05-28 Downgrade Barclays Equal Weight → Underweight
2021-03-29 Iniziato JP Morgan Overweight
2021-03-23 Aggiornamento Jefferies Hold → Buy
2020-09-22 Downgrade Guggenheim Buy → Neutral
2020-06-01 Downgrade Jefferies Buy → Hold
2020-05-14 Reiterato H.C. Wainwright Buy
2020-03-24 Aggiornamento Wedbush Neutral → Outperform
2020-03-04 Iniziato Barclays Equal Weight
2019-11-20 Iniziato Guggenheim Buy
2019-11-11 Downgrade Wedbush Outperform → Neutral
2019-06-13 Iniziato Mizuho Buy
2019-05-14 Iniziato Cantor Fitzgerald Overweight
2019-03-11 Iniziato Barclays Overweight
2018-11-26 Iniziato Piper Jaffray Overweight
2018-10-15 Iniziato Goldman Neutral
2018-09-13 Iniziato H.C. Wainwright Buy
2018-06-01 Iniziato SunTrust Buy
2018-01-05 Iniziato Citigroup Buy
2017-09-08 Iniziato Wedbush Outperform
2017-03-27 Iniziato H.C. Wainwright Buy
2017-03-02 Iniziato Instinet Buy
2017-01-03 Downgrade Oppenheimer Outperform → Perform
2015-11-02 Iniziato Oppenheimer Outperform
Mostra tutto

Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie

pulisher
Jun 17, 2025

CytomX Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView

Jun 17, 2025
pulisher
Jun 17, 2025

CytomX Therapeutics CEO Sells Shares to Meet Tax Obligations - TradingView

Jun 17, 2025
pulisher
Jun 13, 2025

CytomX Therapeutics Approves Key Amendments at Annual Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Stocks in play: Roots Corp. - The Globe and Mail

Jun 13, 2025
pulisher
Jun 11, 2025

Two Sigma Investments LP Cuts Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Cisco Powers AI-Ready Data Centers, From Hyperscale to Enterprise - The Globe and Mail

Jun 10, 2025
pulisher
Jun 09, 2025

GoldMining Announces Closing of Flow-Through Financing and Commences Exploration at Yellowknife Gold Project - The Globe and Mail

Jun 09, 2025
pulisher
Jun 05, 2025

Ballard announces 1.5 MW fuel cell engine order for Sierra Northern Railway - The Globe and Mail

Jun 05, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Grows Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering - MSN

Jun 03, 2025
pulisher
Jun 02, 2025

BMO Lowers Fees on Asset Allocation ETFs to Deliver Greater Value to Investors - The Globe and Mail

Jun 02, 2025
pulisher
May 31, 2025

Millennium Management LLC Grows Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

May 31, 2025
pulisher
May 31, 2025

CytomX stock soars to 52-week high, hits $2.66 By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

CytomX stock soars to 52-week high, hits $2.66 - Investing.com Australia

May 30, 2025
pulisher
May 29, 2025

CytomX Therapeutics CEO Set for Jefferies Conference: Key Biologics Updates Coming - Stock Titan

May 29, 2025
pulisher
May 29, 2025

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference - The Manila Times

May 29, 2025
pulisher
May 20, 2025

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st

May 20, 2025
pulisher
May 20, 2025

CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga

May 20, 2025
pulisher
May 20, 2025

CytomX Therapeutics (CTMX) Maintains "Buy" Rating with $5.00 Price Target | CTMX Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

CytomX begins trial of new melanoma treatment with Merck therapy By Investing.com - Investing.com South Africa

May 19, 2025
pulisher
May 19, 2025

CytomX begins trial of new melanoma treatment with Merck therapy - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

CytomX (CTMX) Advances Phase 1 Study with CX-801 for Metastatic Melanoma | CTMX Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

CytomX Therapeutics Doses First Patient in Phase 1 Study of CX-801 Combined with KEYTRUDA® for Metastatic Melanoma - Nasdaq

May 19, 2025
pulisher
May 19, 2025

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Clinical Trial Breakthrough: CytomX's New Melanoma Drug Combines With Keytruda in Phase 1 Study - Stock Titan

May 19, 2025
pulisher
May 19, 2025

Equities Analysts Set Expectations for CTMX Q2 Earnings - Defense World

May 19, 2025
pulisher
May 18, 2025

What is HC Wainwright’s Estimate for CTMX FY2026 Earnings? - Defense World

May 18, 2025
pulisher
May 17, 2025

CytomX upgraded at H.C. Wainwright on trial data for cancer drug - MSN

May 17, 2025
pulisher
May 17, 2025

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World

May 17, 2025
pulisher
May 17, 2025

CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by HC Wainwright - Defense World

May 17, 2025
pulisher
May 16, 2025

CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st

May 16, 2025
pulisher
May 15, 2025

H.C. Wainwright raises CytomX stock to buy, target to $5.00 By Investing.com - Investing.com South Africa

May 15, 2025
pulisher
May 15, 2025

CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler - GuruFocus

May 15, 2025
pulisher
May 15, 2025

CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler | CTMX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

After pivots and layoffs, CytomX Therapeutics smells success, $100 million payoff - The Business Journals

May 15, 2025
pulisher
May 15, 2025

CytomX stock upgraded at H.C. Wainwright (CTMX:NASDAQ) - Seeking Alpha

May 15, 2025
pulisher
May 15, 2025

HC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX - GuruFocus

May 15, 2025
pulisher
May 15, 2025

H.C. Wainwright raises CytomX stock to buy, target to $5.00 - Investing.com

May 15, 2025
pulisher
May 15, 2025

CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

HC Wainwright Upgrades CytomX Therapeutics to Buy From Neutral, Price Target is $5 - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

CytomX Therapeutics (CTMX) Price Target Doubled Following Promis - GuruFocus

May 15, 2025
pulisher
May 15, 2025

CTMX Stock Upgraded as New Clinical Data Shows Promise | CTMX St - GuruFocus

May 15, 2025
pulisher
May 15, 2025

CytomX Therapeutics (CTMX) Price Target Doubled Following Promising Trial Results | CTMX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

CTMX Stock Upgraded as New Clinical Data Shows Promise | CTMX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates - MSN

May 15, 2025
pulisher
May 14, 2025

Institutional investors have a lot riding on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with 52% ownership - simplywall.st

May 14, 2025
pulisher
May 14, 2025

CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials - Value The Markets

May 14, 2025
pulisher
May 13, 2025

CytomX Therapeutics Secures $93.4 Million Through Stock Sale - TipRanks

May 13, 2025
pulisher
May 13, 2025

CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish? - Seeking Alpha

May 13, 2025
pulisher
May 13, 2025

CytomX (CTMX) Exceeds Revenue Expectations and Advances CRC Drug Development | CTMX Stock News - GuruFocus

May 13, 2025

Cytomx Therapeutics Inc Azioni (CTMX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Cytomx Therapeutics Inc Azioni (CTMX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Ogden Christopher
Chief Financial Officer
Jun 16 '25
Sale
2.69
10,614
28,540
226,271
Ogden Christopher
Chief Financial Officer
Jun 13 '25
Sale
2.95
1,641
4,841
199,385
BELVIN MARCIA
SVP, Chief Scientific Officer
Jun 13 '25
Option Exercise
0.00
37,500
0
286,136
BELVIN MARCIA
SVP, Chief Scientific Officer
Jun 16 '25
Sale
2.69
13,884
37,334
272,252
McCarthy Sean A.
CEO
Jun 13 '25
Option Exercise
0.00
150,000
0
1,145,195
McCarthy Sean A.
CEO
Jun 16 '25
Sale
2.69
55,511
149,264
1,089,684
McCarthy Sean A.
CEO
Mar 18 '25
Sale
0.60
37,656
22,556
995,195
Ogden Christopher
Chief Financial Officer
Mar 18 '25
Sale
0.60
8,551
5,122
201,026
Chu Yu-Waye
Chief Medical Officer
Mar 18 '25
Sale
0.60
4,025
2,411
135,725
ROWLAND LLOYD A
General Counsel
Mar 18 '25
Sale
0.60
10,203
6,112
120,594
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):